Key Takeaways Retatrutide is still in trials early studies show gastrointestinal symptoms and mild injection site reactions
Reduces Inflammation: GLP-1s can help reduce inflammation in the body
The manufacturing base is largely fixed-cost, so pricing pressure at the margin does not destroy unit economics
If youre interested in trying the oral version after stopping the injectable due to side effects, you should definitely talk to your obesity specialist or primary care doctor, says Dr
A few other states are planning or considering obesity drug restrictions in state fiscal year 2026 or 2027, and state interest in expanding coverage of obesity drugs is also waning according to this years survey, with states continuing to report cost as the key factor contributing to obesity drug coverage decisions
Half of our members with coverage pay $50/month or less copay.* We make it simple: Submit your insurance card, and well take care of the rest